These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30345839)

  • 1. New technologies in gene therapy for inducing immune tolerance in hemophilia A.
    Borsotti C; Follenzi A
    Expert Rev Clin Immunol; 2018 Dec; 14(12):1013-1019. PubMed ID: 30345839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in gene therapy for hemophilia: basis, current status, and future perspectives.
    Ohmori T
    Int J Hematol; 2020 Jan; 111(1):31-41. PubMed ID: 30083852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy for Hemophilia.
    Nienhuis AW; Nathwani AC; Davidoff AM
    Mol Ther; 2017 May; 25(5):1163-1167. PubMed ID: 28411016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation.
    Scott DW; Lozier JN
    Br J Haematol; 2012 Feb; 156(3):295-302. PubMed ID: 22055221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia Gene Therapy: Ready for Prime Time?
    VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice.
    Hu C; Lipshutz GS
    Gene Ther; 2012 Dec; 19(12):1166-76. PubMed ID: 22241178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
    Samelson-Jones BJ; Arruda VR
    Front Immunol; 2020; 11():618. PubMed ID: 32425925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Therapy for Hemophilia.
    Nathwani AC; Davidoff AM; Tuddenham EGD
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):853-868. PubMed ID: 28895852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future prospects for hemophilia gene therapy.
    Ward P; Walsh CE
    Expert Rev Hematol; 2016 Jul; 9(7):649-59. PubMed ID: 27153210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy.
    Chen AC; Cai X; Li C; Khoryati L; Gavin MA; Miao CH
    Front Immunol; 2020; 11():638. PubMed ID: 32411127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
    Patel SR; Lundgren TS; Spencer HT; Doering CB
    Front Immunol; 2020; 11():494. PubMed ID: 32351497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to gene and cell therapy for hemophilia.
    Ohmori T; Mizukami H; Ozawa K; Sakata Y; Nishimura S
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S133-42. PubMed ID: 26149014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.
    Finn JD; Ozelo MC; Sabatino DE; Franck HW; Merricks EP; Crudele JM; Zhou S; Kazazian HH; Lillicrap D; Nichols TC; Arruda VR
    Blood; 2010 Dec; 116(26):5842-8. PubMed ID: 20876851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
    Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
    N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What´s new in Gene Therapy of Hemophilia.
    Rodriguez-Merchan EC
    Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.